Vanda Wins Appeal Case on Fanapt U.S. Court of Appeals Affirms District Court s Decision WASHINGTON

Vanda Wins Appeal Case on Fanapt

U.S. Court of Appeals Affirms District Court s Decision

WASHINGTON, April 13, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for

the Federal Circuit affirmed the U.S. District Court for the District of Delaware s decision that West Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, infringed Vanda s U.S. Patent number 8,586,610 (the 610 Patent)

for Fanapt . The 610 Patent is set to expire November 2, 2027.

Pharmaceuticals Inc.

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to

address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

For full U.S. Prescribing Information for Fanapt , including indication, Boxed Warnings and Important

Safety Information, visit our Web site at www.fanapt.com.

Executive Vice President & Chief Financial

Vanda Pharmaceuticals Inc.